Company Overview
Snapshot
Founded in June 2017, Biomica operates with 11–50 employees and has raised $37 million across two funding rounds. Co-founder Yehuda Ringel leads the scientific efforts. In May 2024, the company presented positive clinical data from its ongoing Phase 1 trial of the microbiome-based therapeutic BMC128 for refractory RCC, NSCLC, and melanoma.
Business overview
Biomica is a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based therapeutics. The company targets immune-mediated and infectious diseases, with a particular emphasis on Immuno-Oncology and gastrointestinal disorders. Utilizing its proprietary PRISM (Predictive, high Resolution, Integrative Selection of Microbes) platform, Biomica identifies and targets key microbes, metabolites, and other microbiome-related components to develop both biological and small-molecule approaches. Biomica operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and Drugs Discovery & Development.
Strategic signal
In May 2024, Biomica announced positive clinical data from its ongoing Phase 1 trial for BMC128, a microbiome-based therapeutic targeting refractory RCC, NSCLC, and melanoma. This update signals significant progress in the clinical development of its immuno-oncology pipeline, validating the potential of microbiome-based interventions in challenging cancer indications and demonstrating the company's advancement towards commercialization.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent clinical trial update for Biomica?
- In May 2024, Biomica presented positive clinical data from its ongoing Phase 1 trial of the microbiome-based therapeutic BMC128 for refractory RCC, NSCLC, and melanoma.
- What was a key development in Biomica's immuno-oncology program in early 2024?
- In January 2024, Biomica successfully completed the Phase I trial enrollment for its microbiome-based immuno-oncology drug.
- Which investors participated in Biomica's December 2022 funding round?
- In December 2022, Biomica closed a financing round with investments from Shanghai Healthcare Capital and Evogene.
- What was the purpose of Biomica's collaboration with the Weizmann Institute of Science?
- In October 2019, Biomica collaborated with the Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus, leveraging discoveries in high-resolution crystal structure.
- When did Biomica announce the successful enrollment of the first patient in its Phase I study for BMC128?
- In July 2022, Biomica announced the successful enrollment of the first patient in its Proof-of-Concept Phase I clinical trial for BMC128, a microbiome-based immuno-oncology drug candidate.